KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Travere Therapeutics (TVTX) over the last 13 years, with Q3 2025 value amounting to $86.6 million.

  • Travere Therapeutics' Cash from Investing Activities rose 8772.71% to $86.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.4 million, marking a year-over-year decrease of 6753.17%. This contributed to the annual value of $99.3 million for FY2024, which is 16550.66% up from last year.
  • As of Q3 2025, Travere Therapeutics' Cash from Investing Activities stood at $86.6 million, which was up 8772.71% from $4.8 million recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' Cash from Investing Activities ranged from a high of $104.9 million in Q1 2024 and a low of -$105.7 million during Q1 2021
  • For the 5-year period, Travere Therapeutics' Cash from Investing Activities averaged around -$4.7 million, with its median value being $4.8 million (2025).
  • As far as peak fluctuations go, Travere Therapeutics' Cash from Investing Activities tumbled by 82284.95% in 2023, and later skyrocketed by 38320.96% in 2024.
  • Travere Therapeutics' Cash from Investing Activities (Quarter) stood at $7.4 million in 2021, then tumbled by 597.98% to -$36.7 million in 2022, then skyrocketed by 50.47% to -$18.2 million in 2023, then tumbled by 341.79% to -$80.3 million in 2024, then surged by 207.82% to $86.6 million in 2025.
  • Its Cash from Investing Activities stands at $86.6 million for Q3 2025, versus $4.8 million for Q2 2025 and $41.3 million for Q1 2025.